Trials / Completed
CompletedNCT01694758
OPtimal Type 2 dIabetes Management Including Benchmarking and Standard Treatment in CEEMEA
OPtimal Type 2 dIabetes Management Including Benchmarking and Standard Treatment in CEEMEA (OPTIMISE)
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 733 (actual)
- Sponsor
- AstraZeneca · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
OPTIMISE-CEEMEA is a multinational, multi-centre, observational, prospective study which will include patients suffering from diabetes type 2, treated or untreated, insulin dependent or not insulin dependent. In this study we aim to explore at a primary care level whether the use of benchmarking against a set of guideline-based reference values on a patient basis, may improve quality of patient care, in particular control of diabetes, lipids and blood pressure.
Conditions
Timeline
- Start date
- 2012-11-01
- Primary completion
- 2014-03-01
- Completion
- 2014-03-01
- First posted
- 2012-09-27
- Last updated
- 2014-08-15
Locations
20 sites across 2 countries: Bulgaria, Romania
Source: ClinicalTrials.gov record NCT01694758. Inclusion in this directory is not an endorsement.